A substantially optically pure (S) trans {4 [({2 [({1 [3 5 bis(trifluoromethyl) phenyl] ethyl}{5 [2 (methylsulfonyl) ethoxy] pyrimidine 2 yl} amino) methyl] 4 (trifluoromethyl) phenyl} (ethyl) amino) methyl] cyclohexyl} aceitic acid having the effect of reducing the amount of PCSK9 proteins and increasing the amount...

Provided is a pharmacotherapy for preventing glaucoma or preventing or treating ocular hypertension which has potent and immediate intraocular pressure lowering action and exhibits prolonged duration of the action. A combination of (S) ( ) 1 (4 fluoro 5 isoquinolinesulfonyl) 2 methyl 1 4 homopiperazine a salt there...

The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis , hypercholesterolemia , low HDL blood disease in mammals including humans. A pharmaceutical composition for t...

The present invention provides a compound useful in the prevention and treatment of nonalcoholic fatty liver disease. The invention relates to a drug for the prevention and/or treatment of nonalcoholic fatty liver disease the drug having as an active ingredient (R) 2 [3 [[N (benzoxazol 2 yl) N 3 (4 methoxyphenoxy)pr...

20172800Provided is a novel JAK3 inhibitor useful as a preventive and/or therapeutic agent for organ transplant rejection, graft versus host disease (GvHD), rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjogren’s syndrome, Behcet"s disease, type I diabetes mellitus, autoimmune thyroiditis, ...

This invention provides a combination drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states such as hyper LDL cholesterolemia in mammals including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like said...

1231236 106 101 101 103 63 6Disclosed is a method that is for producing 1 bromo 1 [3 5 bis(trifluoromethyl)phenyl] ethane having high optical purity and that is a method containing a step for brominating optically active 1 [3 5 bis(trifluoromethyl)phenyl] ethanol using as a brominating agent either a) the combinatio...

Provided is a technique for suppressing color change of an aqueous composition comprising a halogenated isoquinoline derivative during storage at a high temperature. An aqueous composition comprising a compound represented by general formula (1) [wherein X represents a halogen atom] a salt thereof or a solvate of t...

Provided is a technique for suppressing the precipitation of crystals of an aqueous composition comprising a halogenated isoquinoline derivative during storage at a low temperature. An aqueous composition comprising a compound represented by general formula (1) [wherein X represents a halogen atom] a salt thereof o...

Provided is an intraocular lens having a novel structure with high utility which is easy to adapt to patients and can improve quality of vision (QOV). In an intraocular lens (10) an optical characteristic is set rotationally symmetric around the optical axis and a spherical aberration of a magnitude corresponding to...

Provided is a technique which in the design of intraocular lenses simplifies design work and makes it possible for aberration of the entire eyeball to more precisely match a target value when the designed intraocular lens is inserted into a patient s eye. This intraocular lens design method involves deriving an intr...

The present invention provides: a compound represented by general formula (I) below that has both angiotensin II receptor antagonism and a PPAR activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure cardiac disease arteriosclerosis type 2 diabetes and the like; and a ...

It is to provide a novel LXRp agonist useful as 'a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as alle...

A medicinal composition with excellent stability which contains a mixture of cross carmelose sodium and a substance selected from the group consisting of 2,2−dichloro−12−(4−chlorophenyl)dodecanoic acid, salts thereof, and esters thereof.

A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halo(lower alkyl) group, cyano group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7, R8, R9 and R10 represent hydrogen atom, a halogen atom, a lower alkyl group, a ha...

By compression-molding a mixed powder of a useful bacterium, crystalline cellulose/light anhydrous silicic acid (an excipient that is produced by mixing crystalline cellulose and a small amount of light anhydrous silicic acid in the slurry form and then by spray-drying it) and a starch-containing saccharide (a star...

It is to provide a novel LXRß agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such ...

Provided is a novel JAK3 inhibitor useful as a preventive and/or therapeutic agent for organ transplant rejection, graft versus host disease (GvHD), rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjogren’s syndrome, Behcet""s disease, type I diabetes mellitus, autoimmune thyroiditis, idiopat...

Provided is a polymerizable UV- absorbing colorant monomer which exhibits excellent stability under alkaline conditions and which is for a polymer that is useful as an intraocular lens material. A compound represented by general formula (1) is used as a polymerizable UV absorbing colorant monomer for a polymer for a...

The present invention is a method of manufacturing a compound represented by the following Formula (3) by reacting a compound represented by the following Formula (1) with a compound represented by the following Formula ( 2 ) , which comprises a treatment process using an acid or base. [in the formula, R1 repre...

Provided is a method for improving the optical purity of optically active 2 hydroxycarboxylic acids that are useful as raw materials in the manufacture of drugs agricultural chemicals and industrial products. A method for improving the optical purity of hydroxycarboxylic acids represented by general formula (Ia) or ...

A method for preparing a trans-{4-[(alkylamino)methyl]cyclohexyl}acetic acid, which is useful as a raw material compound for manufacture of medicaments and the like, comprising the step of reducing amide group of a compound represented by the following general formula (6) (R1 represents hydrogen atom or a C1-6 al...

Provided are: a cloth including thermoplastic synthetic staple fibers, especially a woven or knitted fabric in which occurrence of pilling is suppressed and a reduction of the strength or deterioration of the texture of the cloth is suppressed; and a method for manufacturing the cloth. An anti-pilling cloth includin...

To provide a technique for improving the stability of a halogenated isoquinoline derivative with respect to light in an aqueous composition. A pharmaceutical preparation that is obtained by having an aqueous composition which contains a compound represented by general formula (1) a salt thereof or a solvate of the c...

The purpose of the present invention is to provide an aqueous composition having an excellent antiseptic effect. The aqueous composition contains: a compound expressed by the following general formula (1) [in this formula X represents a halogen atom] a salt thereof or a solvate thereof; and a quaternary ammonium typ...

Provided is a technology of inhibiting a change in color of a halogenated isoquinoline derivative containing aqueous composition during storage at high temperature. This pharmaceutical preparation comprises an aqueous composition which contains a compound represented by general formula (1) [where X represents a halo...

This cross section image capture device is provided with the following: a cross section image capture means for scanning measurement light onto the ocular fundus of an eye under test E and capturing a cross section of the eye under test ocular fundus; and an image processing means for compressing the captured image ...

Provided is a technique for suppressing color change of an aqueous composition comprising a halogenated isoquinoline derivative during storage at a high temperature. An aqueous composition comprising a compound represented by general formula (1) [wherein X represents a halogen atom] a salt thereof or a solvate of th...

Provided is a toric intraocular lens whereby pushing out of the toric intraocular lens by an intraocular-lens insertion instrument can be further stabilized. The toric intraocular lens according to the present invention is configured having a lens body having a flattest meridian and a steepest meridian a pair of sup...

The present invention realizes a toric ocular lens having an edge whereby a lens conducive to preventing cataract can be designed without reducing the degree of freedom of lens design. The toric ocular lens according to the present invention is configured so that a substantially flat part in which the edge thickness...

Provided is an intraocular lens insertion instrument that can further stabilize the behavior of an intraocular lens. This intraocular lens insertion instrument has: a substantially cylindrical instrument main body having, at the distal end thereof, an insertion tube part for inserting into an eye, in a folded state,...

A novel inhalant is provided as a COVID-19 therapeutic agent. The present invention relates to an inhalant characterized by containing cepharanthine.

compound represented by the following general formula (1): [wherein m is an integer of 0 to 4; n is an integer of 5 to 9; and W represents -CH(OR)- (R represents hydrogen or a hydroxy-protecting group) or -C(=O)-], a salt of the compound, or an ester of the compound. The compound, salt, or ester is effective in blo...

To allow imaging light to be appropriately received by a second camera in the case where a first imaging mode (color imaging mode) is changed to a second imaging mode (autofluorescence imaging mode). [Solution] In the first imaging mode using a dichroic mirror 30 allows light LB to be received by both a first camera...

Provided is a toric intraocular lens that improves the visibility of the toric axis. The toric intraocular lens is a toric intraocular lens having a lens body provided with an astigmatic axis configured such that a mark indicating the astigmatic axis is formed on the optical surface of the outer edge portion of the ...

The present invention achieves an intraocular lens having a wider range of application, from the standpoint of characteristics during the flexure of support parts, in comparison to the range of application of a single conventional intraocular lens. This intraocular lens includes: an optical part that has a prescribe...

Provided is an intraocular lens insertion instrument that reduces the stress on ocular tissues and enables stable insertion of an intraocular lens. This intraocular lens insertion instrument has: a substantially-cylindrical insertion member which is to be inserted inside an eye; an opening which is provided to the l...

Provided is an acellular root canal filler that comprises a tetrahydroisoquinoline compound, a pharmaceutically acceptable salt thereof or a solvate of the same. Also provided is an acellular dental tissue regeneration promoting kit that comprises a pretreating agent containing serine protease and the acellular root...

The present invention addresses the problem of providing a woven fabric that has flexibility, and a high stretchability and stretch recovery ratio in a weft direction and a bias direction. A solution to the problem is a stretchable woven fabric that has a multiple-weave structure. The multiple-weave structure includ...

This multiplexer 100 comprises an input unit 11 to which a plurality of image signals respectively acquired by a plurality of imaging devices 2 and based on a first data communication standard are inputted, an output unit 14 for outputting image signals based on a second data communication standard the data transfer...

The present invention provides a multifocal diffraction lens capable of efficiently using light. A multifocal diffraction lens 100 has a diffraction grating 1c. Minus-order light L2 generates a focal point f2 for distant vision, zero-order light L1 generates a focal point f1 that is closer than that for distant visi...

A housing unit 3 comprises: a hollow casing 31; and a rotary window 4 disposed at an opening of the casing 31. The rotary window 4 includes: a window 41 that has light transmissivity; a window frame 42 that supports the window 41 at a peripheral edge thereof; and a driven means 54 provided to the outer periphery of ...

The present invention provides a novel copolymer utilizable for drug delivery technology. The present invention pertains to a drug complex in which a target recognition molecule is bound to a copolymer X comprising structural units represented by the following formulae (a), (b) and (c). [In the formulae, R1, R2, and...

A multiplexer 100 according to the present invention comprises: an input unit 11 to which multiple image signals acquired by the respective ones of multiple imaging devices 2 and based on a first data communication standard are inputted; an output unit 14 that outputs a signal based on a second data communication st...

This electric power storage/discharge system (100) comprises a power generation unit (2A) that has a first internal resistance and that supplies DC power from an output terminal and a storage battery (1) that is connected in parallel with the output terminal of the power generation unit (2A) and that has a second in...